ARTA
VRTX icon

A.R.T. Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

A.R.T. Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,824
Closed -$667K – 105
2020
Q4 		$667K Buy
+2,824
New +$648K 3.09% 4
2019
Q4 		– Sell
-2,455
Closed -$416K – 1760
2019
Q3 		$416K Sell
2,455
-10,200
-81% -$1.8M 0.02% 928
2019
Q2 		$2.32M Sell
12,655
-300
-2% -$52.4K 0.13% 202
2019
Q1 		$2.38M Sell
12,955
-21,245
-62% -$3.92M 0.14% 194
2018
Q4 		$5.67M Buy
34,200
+7,100
+26% +$1.23M 0.36% 36
2018
Q3 		$5.22M Sell
27,100
-26,700
-50% -$4.75M 0.24% 85
2018
Q2 		$9.14M Sell
53,800
-33,200
-38% -$5.15M 0.37% 35
2018
Q1 		$14.2M Buy
87,000
+83,600
+2,459% +$13.7M 0.57% 8
2017
Q4 		$509K Sell
3,400
-30,800
-90% -$4.56M 0.02% 887
2017
Q3 		$5.2M Sell
34,200
-6,200
-15% -$933K 0.27% 71
2017
Q2 		$5.21M Sell
40,400
-66,400
-62% -$7.99M 0.28% 62
2017
Q1 		$11.7M Buy
106,800
+70,600
+195% +$6.22M 0.54% 16
2016
Q4 		$2.67M Buy
36,200
+25,200
+229% +$2.05M 0.16% 180
2016
Q3 		$959K Sell
11,000
-3,669
-25% -$347K 0.31% 76
2016
Q2 		$1.26M Sell
14,669
-47,100
-76% -$4.07M 0.06% 461
2016
Q1 		$4.91M Buy
61,769
+11,800
+24% +$1.07M 0.22% 102
2015
Q4 		$6.29M Sell
49,969
-48,396
-49% -$5.84M 0.3% 56
2015
Q3 		$10.2M Buy
98,365
+60,474
+160% +$7.77M 0.38% 42
2015
Q2 		$4.68M Buy
+37,891
New +$4.77M 0.16% 169
2014
Q2 		– Sell
-88,742
Closed -$6.28M – 1551
2014
Q1 		$6.28M Buy
+88,742
New +$7.03M 0.33% 59
2013
Q4 		– Sell
-98,173
Closed -$7.44M – 1533
2013
Q3 		$7.44M Buy
98,173
+102
+0.1% +$8.12K 0.41% 27
2013
Q2 		$7.85M Buy
+98,071
New +$7.22M 0.26% 83

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

A.R.T. Advisors's VRTX Position: Q1 2021 in Review

A.R.T. Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2021, closing a stake of 2,824 shares — an estimated $667K sold.

A.R.T. Advisors first reported a position in VRTX in Q2 2013 and held it in 22 quarters. The position peaked at $14.2M in Q1 2018. 999 funds tracked by Wall St. Rank hold VRTX as of Q1 2021.

  • A.R.T. Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • A.R.T. Advisors sold 2,824 Vertex Pharmaceuticals shares in Q1 2021, an estimated $667K.
  • A.R.T. Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 22 quarters.
  • A.R.T. Advisors's Vertex Pharmaceuticals position peaked at $14.2M in Q1 2018.
  • 999 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2021.

Based on A.R.T. Advisors's 13F filing for Q1 2021, filed 17 May 2021.